Company Overview
About Freenome
Freenome is a clinical-stage biotechnology company founded in 2014 and headquartered in South San Francisco, California. The company is developing a multiomics blood-based testing platform for the early detection of cancer — combining genomics, proteomics, metabolomics, and epigenomics signals from a single blood draw and applying AI/ML models to distinguish cancer-derived signals from normal biological variation. Its lead program targets colorectal cancer (CRC) screening, aiming to provide a non-invasive alternative to colonoscopy for the millions of Americans who decline or delay guideline-based screening.
Business Model & Competitive Advantage
Freenome has raised over $1.1 billion in total funding, including a landmark $290 million investment from Roche in January 2022 alongside an international licensing and collaboration agreement. In late 2024, Freenome signed an exclusive license with Exact Sciences for its blood-based CRC screening test — including a $75 million upfront payment, $200 million in potential milestone payments, and up to $500 million more if the test receives a USPSTF A or B recommendation. In December 2025, Freenome announced a SPAC business combination with Perceptive Capital Solutions Corp, including $240 million from institutional investors, to create a publicly listed company trading on Nasdaq under ticker FRNM, with the transaction expected to close in H1 2026.
Competitive Landscape 2025–2026
Freenome''s AI/ML-enabled multiomics approach differentiates it from single-analyte liquid biopsy companies by integrating multiple biological signal types into a composite cancer risk model. Its platform competes with Exact Sciences (Cologuard), Grail (Galleri multi-cancer early detection), and Guardant Health (Shield blood-based CRC test) for the emerging blood-based cancer screening market — a segment that analysts expect to grow significantly as clinical validation matures and payor coverage expands.
Key Differentiators
Strong Challenger
Freenome is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Freenome with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Freenome? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Freenome Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Freenome vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →